Peptide aggregation in neurodegenerative disease

Annual Review of Biomedical Engineering

Volumn 4, Issue , 2002, Pages 155-174

  Murphy, Regina M ^a  

^a University of Wisconsin Madison   (United States)

Author keywords

Alzheimer's disease; Amyloid; Beta amyloid peptide; Huntington's disease; Prion

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; DEGENERATIVE DISEASE; HUNTINGTON CHOREA; NERVE DEGENERATION; PEPTIDE ANALYSIS; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; X RAY DIFFRACTION;

AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; CATTLE; HUMANS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NUCLEAR PROTEINS; PRIONS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ANALYSIS, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036407227     PISSN: 15239829     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.bioeng.4.092801.094202     Document Type: Review

References (96)

1. McGowan DP, van Roon-Mom W, Holloway H, Bates GP, Mangiarini L, et al. 2000. Amyloid-like inclusions in Huntington's disease. Neuroscience 100:677-80
2. Vassar R, Citron M. 2000. Abetagenerating enzymes: Recent advances in beta- and gamma-secretase research. Neuron 27:419-22
3. Evert BO, Wullner U, Klockgether T. 2000. Cell death in polyglutamine diseases. Cell Tissue Res. 301:189-204
4. Mende-Mueller LM, Toneff T, Hwang SR, Chesselet MF, Hook VY. 2001. Tissue-specific proteolysis of Huntingtin (htt) in human brain: Evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. J. Neurosci. 21:1830-37
5. Caughey B. 2000. Transmissible spongiform encephalopathies, amyloidoses and yeast prions: Common threads? Nat. Med. 6:751-54
6. Kallberg Y, Gustafsson M, Persson B, Thyberg J, Johansson J. 2001. Prediction of amyloid fibril-forming proteins. J. Biol. Chem. 276:12945-50
7. Chiti F, Taddei N, Bucciantini M, White P, Ramponi G, Dobson CM. 2000. Mutational analysis of the propensity for amyloid formation by a globular protein. EMBO J. 19:1441-49
8. West MW, Wang W, Patterson J, Mancias JD, Beasley JR, Hecht MH. 1999. De novo amyloid proteins from designed combinatorial libraries. Proc. Natl. Acad. Sci. USA 96:11211-16
9. Barrow CJ, Yasuda A, Kenny PT, Zagorski MG. 1992. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J. Mol. Biol. 225:1075-93
10. Talafous J, Marcinowski KJ, Klopman G, Zagorski MG. 1994. Solution structure of residues 1-28 of the amyloid beta-peptide. Biochemistry 33:7788-96
11. Kohno T, Kobayashi K, Maeda T, Sato K, Takashima A. 1996. Three-dimensional structures of the amyloid beta peptide (25-35) in membrane-mimicking environment. Biochemistry 35:16094-104
12. Fraser PE, Nguyen JT, Surewicz WK, Kirschner DA. 1991. pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys. J. 60:1190-201
13. Fraser PE, McLachlan DR, Surewicz WK, Mizzen CA, Snow AD, et al. 1994. Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues. J. Mol. Biol. 244:64-73
14. Zhang Y, Swietnicki W, Zagorski MG, Surewicz WK, Sonnichsen FD. 2000. Solution structure of the E200K variant of human prion protein. Implications for the mechanism of pathogenesis in familial prion diseases. J. Biol. Chem. 275:33650-54
15. Massi F, Peng JW, Lee JP, Straub JE. 2001. Simulation study of the structure and dynamics of the Alzheimer's amyloid peptide congener in solution. Biophys. J. 80:31-44
16. Ragg E, Tagliavini F, Malesani P, Monticelli L, Bugiani O, et al. 1999. Determination of solution conformations of PrP106-126, a neurotoxic fragment of prion protein, by 1H NMR and restrained molecular dynamics. Eur. J. Biochem. 266:1192-200
17. De Gioia L, Selvaggini C, Ghibaudi E, Diomede L, Bugiani O, et al. 1994. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J. Biol. Chem. 269:7859-62
18. Nguyen J, Baldwin MA, Cohen FE, Prusiner SB. 1995. Prion protein peptides induce a-helix to b-sheet conformational transition. Biochemistry 34:4186-92
19. Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, et al. 2000. NMR solution structure of the human prion protein. Proc. Natl. Acad. Sci. USA 97:145-50
20. Thompson A, White AR, McLean C, Masters CL, Cappai R, Barrow CL. 2000. Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of PrP(C). J. Neurosci. Res. 62:293-301
21. Swietnicki W, Morillas M, Chen SG, Gambetti P, Surewicz WK. 2000. Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry 39:424-31
22. Salmona M, Malesani P, De Gioia L, Gorla S, Bruschi M, et al. 1999. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochem. J. 342:207-14
23. Hosszu LL, Baxter NJ, Jackson GS, Power A, Clarke AR, et al. 1999. Structural mobility of the human prion protein probed by backbone hydrogen exchange. Nat. Struct. Biol. 6:740-43
24. Maiti NR, Surewicz WK. 2001. The role of disulfide bridge in the folding and stability of the recombinant human prion protein. J. Biol. Chem. 276:2427-31
25. Jackson GS, Hosszu LL, Power A, Hill AF, Kenney J, et al. 1999. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 283:1935-37
26. Guilbert C, Ricard F, Smith JC. 2000. Dynamic simulation of the mouse prion protein. Biopolymers 54:406-15
27. Inouye H, Bond J, Baldwin MA, Ball HL, Prusiner SB, Kirschner DA. 2000. Structural changes in a hydrophobic domain of the prion protein induced by hydration and by Ala → Val and Pro → Leu substitutions. J. Mol. Biol. 300:1283-96
28. Perutz MF, Johnson T, Suzuki M, Finch JT. 1994. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 91:5355-58
29. Monoi H, Futaki S, Kugimiya S, Minakata H, Yoshihara K. 2000. Poly-L-glutamine forms cation channels: Relevance to the pathogenesis of the polyglutamine diseases. Biophys. J. 78:2892-99
30. Fraser PE, Duffy LK, O'Malley MB, Nguyen J, Inouye H, Kirschner DA. 1991. Morphology and antibody recognition of synthetic beta-amyloid peptides. J. Neurosci. Res. 28:474-85
31. Stine WB Jr, Snyder SW, Ladror US, Wade WS, Miller MF, et al. 1996. The nanometer-scale structure of amyloidbeta visualized by atomic force microscopy. J. Protein Chem. 15:193-203
32. Harper JD, Wong SS, Lieber CM, Lansbury PT Jr. 1999. Assembly of A beta amyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38:8972-80
33. Blackley HK, Sanders GH, Davies MC, Roberts CJ, Tendler SJ, Wilkinson MJ. 2000. In-situ atomic force microscopy study of beta-amyloid fibrillization. J. Mol. Biol. 298:833-40
34. Malinchik SB, Inouye H, Szumowski KE, Kirschner DA. 1998. Structural analysis of Alzheimer's beta(1-40) amyloid: Protofilament assembly of tubular fibrils. Biophys. J. 74:537-45A
35. Kheterpal I, Zhou S, Cook KD, Wetzel R. 2000. Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. Proc. Natl. Acad. Sci. USA 97:13597-601
36. Tjemberg LO, Callaway DJ, Tjemberg A, Hahne S, Lilliehook C, et al. 1999. A molecular model of Alzheimer amyloid beta-peptide fibril formation. J. Biol. Chem. 274:12619-25
37. Serpell LC, Blake CC, Fraser PE. 2000. Molecular structure of a fibrillar Alzheimer's A beta fragment. Biochemistry 39:13269-75
38. Benzinger TL, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, et al. 2000. Two-dimensional structure of betaamyloid(10-35) fibrils. Biochemistry 39:3491-99
39. Antzutkin ON, Balbach JJ, Leapman RD, Rizzo NW, Reed J, Tycko R. 2000. Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of beta-sheets in Alzheimer's betaamyloid fibrils. Proc. Natl. Acad. Sci. USA 97:13045-50
40. Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, et al. 1993. Neurotoxicity of a prion protein fragment. Nature 362:543-46
41. Baskakov IV, Legname G, Prusiner SB, Cohen FE. 2001. Folding of prion protein to its native alpha-helical conformation is under kinetic control. J. Biol. Chem. 276:19687-90
42. Jobling MF, Stewart LR, White AR, McLean C, Friedhuber A, et al. 1999. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126. J. Neurochem. 73:1557-65
43. Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, et al. 1999. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. USA 96:4604-9
44. Jarrett JT, Berger EP, Lansbury PT Jr. 1993. The C-terminus of the beta protein is critical in amyloidogenesis. Ann. NY Acad. Sci. 695:144-48
45. Tomski SJ, Murphy RM. 1992. Kinetics of aggregation of synthetic betaamyloid peptide. Arch. Biochem. Biophys. 294:630-38
46. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, et al. 1994. Amyloid-beta aggregation: Selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67:1216-28
47. Lomakin A, Teplow DB, Kirschner DA, Benedek GB. 1997. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc. Natl. Acad. Sci. USA 94:7942-47
48. Inouye H, Kirschner DA. 2000. A beta fibrillogenesis: Kinetic parameters for fibril formation from congo red binding. J. Struct. Biol. 130:123-29
49. Pallitto MM, Murphy RM. 2001. A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. Biophys. J. 81:1805-22
50. Post K, Pitschke M, Schafer O, Wille H, Appel TR, et al. 1998. Rapid acquisition of beta-sheet structure in the prion protein prior to multimer formation. Biol. Chem. 379:1307-17
51. Wildegger G, Liemann S, Glockshuber R. 1999. Extremely rapid folding of the C-terminal domain of the prion protein without kinetic intermediates. Nat. Struct. Biol. 6:550-53
52. Harrison PM, Chan HS, Prusiner SB, Cohen FE. 2001. Conformational propagation with prion-like characteristics in a simple model of protein folding. Protein Sci. 10:819-35
53. Tseng BP, Esler WP, Clish CB, Stimson ER, Ghilardi JR, et al. 1999. Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry 38:10424-31
54. Esler WP, Stimson ER, Jennings JM, Vinters HV, Ghilardi JR, et al. 2000. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 39:6288-95
55. Esler WP, Felix AM, Stimson ER, Lachenmann MJ, Ghilardi JR, et al. 2000. Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid. J. Struct. Biol. 130:174-83
56. Cohen FE, Prusiner SB. 1998. Pathologic conformations of prion proteins. Annu. Rev. Biochem. 67:793-819
57. Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D. 1999. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. USA 96:11404-9
58. Stumpf MP, Krakauer DC. 2000. Mapping the parameters of prion-induced neuropathology. Proc. Natl. Acad. Sci. USA 97:10573-77
59. Kellershohn N, Laurent M. 1998. Species barrier in prion diseases: A kinetic interpretation based on the conformational adaptation of the prion protein. Biochem. J. 334:539-45
60. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. 1993. Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci. 13:1676-87
61. Shearman MS, Ragan CI, Iversen LL. 1994. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. Proc. Natl. Acad. Sci. USA 91:1470-74
62. Seilheimer B, Bohrmann B, Bondolfi L, Muller F, Stuber D, Dobeli H. 1997. The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. J. Struct. Biol. 119:59-71
63. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, et al. 1996. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271:20631-35
64. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, et al. 1999. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19:8876-84
65. Ward RV, Jennings KH, Jepras R, Neville W, Owen DE, et al. 2000. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem. J. 348(Pt 1):137-44
66. Ettaiche M, Pichot R, Vincent JP, Chabry J. 2000. In vivo cytotoxicity of the prion protein fragment 106-126. J. Biol. Chem. 275:36487-90
67. Brown DR. 2000. Prion protein peptides: Optimal toxicity and peptide blockade of toxicity. Mol. Cell Neurosci. 15:66-78
68. Wille H, Prusiner SB, Cohen FE. 2000. Scrapie infectivity is independent of amyloid staining properties of the Nterminally truncated prion protein. J. Struct. Biol. 130:323-38
69. Li H, Li SH, Johnston H, Shelbourne PF, Li XJ. 2000. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet. 25:385-89
70. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, et al. 1999. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46:842-49
71. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, et al. 2000. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 275:19831-38
72. Bence NF, Sampat RM, Kopito RR. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552-55
73. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. 1999. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 23:425-28
74. Carmichael J, Chatellier J, Woolfson A, Milstein C, Fersht AR, Rubinsztein DC. 2000. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc. Natl. Acad. Sci. USA 97:9701-5
75. Ferrigno P, Silver PA. 2000. Polyglutamine expansions: Proteolysis, chaperones, and the dangers of promiscuity. Neuron 26:9-12
76. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. 1995. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease. Nat. Med. 1:143-48
77. Lorenzo A, Yankner BA. 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 91:12243-47
78. Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, et al. 2000. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. USA 97:6739-44
79. Klunk WE, Debnath ML, Koros AM, Pettegrew JW. 1998. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci. 63:1807-14
80. Howlett DR, Perry AE, Godfrey F, Swatton JE, Jennings KH, et al. 1999. Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. Biochem. J. 340:283-89
81. Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, et al. 1996. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J. Biol. Chem. 271:6839-44
82. Caughey WS, Raymond LD, Horiuchi M, Caughey B. 1998. Inhibition of proteaseresistant prion protein formation by porphyrins and phthalocyanines. Proc. Natl. Acad. Sci. USA 95:12117-22
83. Reixach N, Crooks E, Ostresh JM, Houghten RA, Blondelle SE. 2000. Inhibition of beta-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library. J. Struct. Biol. 130:247-58
84. Kuner P, Bohrmann B, Tjemberg LO, Naslund J, Huber G, et al. 2000. Controlling polymerization of beta-amyloid and prion-derived peptides with synthetic small molecule ligands. J. Biol. Chem. 275:1673-78
85. Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, et al. 2001. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 98:4764-69
86. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. 1997. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA 94:4109-12
87. Tjemberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, et al. 1996. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271:8545-48
88. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. 1998. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat. Med. 4:822-26
89. Hughes E, Burke RM, Doig AJ. 2000. Inhibition of toxicity in the beta-amyloid peptide fragment beta-(25-35) using N-methylated derivatives: A general strategy to prevent amyloid formation. J. Biol. Chem. 275:25109-15
90. Ghanta J, Shen CL, Kiessling LL, Murphy RM. 1996. A strategy for designing inhibitors of beta-amyloid toxicity. J. Biol. Chem. 271:29525-28
91. Findeis MA, Musso GM, Arico-Muendel CC, Benjamin HW, Hundal AM, et al. 1999. Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry 38:6791-800
92. Pallitto MM, Ghanta J, Heinzelman P, Kiessling LL, Murphy RM. 1999. Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry 38:3570-78
93. Lowe TL, Strzelec A, Kiessling LL, Murphy RM. 2001. Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry 40:7882-89
94. Chabry J, Priola SA, Wehrly K, Nishio J, Hope J, Chesebro B. 1999. Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J. Virol. 73:6245-50
95. Horiuchi M, Baron GS, Xiong LW, Caughey B. 2001. Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J. Biol. Chem. 276:15489-97
96. Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, et al. 2000. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J. Biol. Chem. 275:10437-42